NCT04991870View on ClinicalTrials.gov

Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM

PHASE1RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 28, 2023

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Recurrent GliosarcomaRecurrent Supratentorial GlioblastomaSupratentorial Gliosarcoma
Interventions
BIOLOGICAL

Cord Blood-derived Expanded Allogeneic Natural Killer Cells

Given CB-NK-TGF-betaR2-/NR3C1- intratumorally

PROCEDURE

Resection

Undergo surgical resection

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER